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1. Introduction 
The last two decades have registered a progressive decline of both the incidence and 
mortality rates for some human cancers, worldwide (Jemal et al., 2010). However, in the 
same time interval, the incidence of cutaneous melanoma (CM), has progressively increased 
(Gallagher et al., 2005; Jemal et al., 2010), up to an epidemic level in Western countries and 
Australia (Beddingfield et al., 2003; Cancer facts & Figures, 2009). To date, the average 
lifetime risk for developing melanoma ranges from 1/50 in the United States (men and 
women) (Meyle & Guldberg, 2009; Horner et al. 2011) up to 1/25 for Australian men 
(Hocker et al., 2008). CM is an extremely aggressive skin cancer, and constitutes one of the 
most lethal human malignancies, notwithstanding the progressive increase of early 
diagnosis and surgical excision registered from 1990s. This poor prognosis may be due, at 
least in part, to the possible occurrence of metastasis even in early phases of melanoma 
progression, as well as to the very low response to current systemic therapy. The 5 year-
survival rate for patients with disseminated disease is about 10%, with death for disease 
ultimately occurring within 2 years from metastases (Balch et al., 2000; Chin et al., 2006; 
Zbytek et al., 2008; Ugurel et al., 2009; Cancer facts & Figures, 2009). This underscores the 
need to uncover the mechanisms underlying melanoma biology, with the aim to identify 
reliable early markers of response and to select patients eligible for new rational avenues for 
therapy (Siena et al., 2009). The formidable aggressive potential of CM is thought to 
represent the result of multiple intersecting molecular alterations of the control pathways 
governing cell proliferation, cell death, DNA-repair, and tumor-stromal interaction. These 
molecular alterations are thought to be involved also in the peculiar histomorphological 
features and different biological behavior of the four “classical” types of CM. Three of them 
(superficial spreading melanoma, SSM; malignant lentigo melanoma, LM; acral melanoma, 
AM) are characterized by the sequential progression from junctional (radial) and pagetoid 
(intraepithelial) growth phase, to invasive (vertical) growth. The radial growth phase (RGP) 
is characterized by lateral melanocyte growth at the dermo-epidermal interface (junctional 
area), whereas the vertical growth phase (VGP) shows the spreading of melanoma cells into 
the dermis and subcutis, this being correlated with the occurrence of metastasis. The fourth 
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
36
type of CM, the “nodular” melanoma (NM), shows an ab initio invasive growth, and a more 
aggressive clinical course. Considerable insights have recently been made with respect to 
these topics. An impressive number of putative biomarkers of CM progression and drug 
response are being increasingly proposed, and new hypotheses concerning the 
interrelationship between histopathological features and clinical behavior are in progress. 
To date, however, we have to face with an “overload” of research data, which has already 
had a great impact on our understanding of melanoma progression, but is only beginning to 
unravel the real complexity of CM biology. Further work is required before we definitively 
know how we can use correctly these data to fight melanoma. We here review the more 
recent advances in molecular events involved in melanoma progression, drawing on a 
limited set of examples focused on the seminal findings of several research groups that have 
provided insight on melanoma biology. We discuss also the surprising interactions between 
some of these molecular pathways, both at genetic and epigenetic level, with particular 
attention to their role in defining potential markers for prognosis and therapeutic 
management of melanoma patients. 
2. Genetics 
Since the announcement of the completion of the Human Genome Project in 2003 (Noble, 
2003), the first comprehensive analysis of cancer genomes has been completed: the entire 
genome of cutaneous melanoma and lung cancer has been sequenced. This formidable 
amount of information concerning the specific mutations of these cancer types will be of 
paramount importance in our understanding of the key molecular events that determine 
cancer evolution in every single patient. In tumors, most mutations are "passengers", 
meaning that they do not contribute to oncogenesis. Still, they provide information about 
the various steps leading to the oncogenic transformation of cells, as occurs, for example, for 
UV-exposure in skin cancer. This kinds of mutation, then, are very useful to study the 
pathogenesis of cancer. Only a small subset of somatic mutations is made of "driver 
mutations", which confer the oncogenic stigmata to cancer cells, being thus eligible for 
diagnosis and molecular therapy (Stratton et al, 2009). To date, more than 300 "driver" genes 
have been identified across all human cancers. Not surprisingly, they all converge over the 
few key cellular pathways which regulate cell life and differentiation (Vogelstein, 2010). The 
development and progression of melanoma is characterized by the acquisition of 
chromosomal deletions, amplification and gene mutations (Chin et al., 2006). The many gene 
expression profile studies performed up to now have evidenced that melanomas show 
significant genetic heterogeneity (Fecher et al., 2007; Ryu et al., 2007). Overall, large regions 
of the genome exhibiting DNA copy number changes and genes relevant for melanoma 
progression (Lin et al., 2008) as the Wnt5a, which misregulation results in increased motility 
in melanoma, have been identified (Lin et al., 2008). This also occurs for genes fundamental 
for basic melanocyte biology, such as Rab38, involved in melanosomal protein trafficking. 
We here refer to several genetic changes specifically linked to particular aspects of 
melanoma biology.  
2.1 UVR 
The dominant mutational signature emerging from sequencing the entire genome of 
cutaneous melanoma (Stratton et al, 2009) reflects DNA damage due to ultraviolet light 
exposure. Ultra-Violet Radiation (UVR) exerts direct or indirect damaging effects on nucleic 
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acids and proteins (Kyrgidis et al., 2010). UVA mutate DNA indirectly, via absorption by 
non-DNA endogenous sensitizers which generate Reactive Oxygen Species (ROS) 
responsible for DNA damage (Lund & Timmins, 2007).  UVB directly cause two types of 
DNA lesions: cyclobutane pyrimidine dimers (CPDs), arising between adjacent thymine(T) 
or cytosine(C) residues, and -pyrimidine 4-pyrimidone photoproducts (6-4PP) . The ‘‘UVB 
signature mutations” are characterized by CT→T and CC→TT transitions. Variants in 
MC1R, ASIP, TYR and TYRP1 have been identified as independent low-penetrance 
susceptibility genes for UV-induced melanomagenesis. These genes seem to contribute to 
the interrelation between pigmentation, cutaneous phototypes and exposure to UV light in 
affecting predisposition to melanoma (Thompson et al., 2009). Moreover, in melanomas of 
photoexposed skin, we have found defective expression of the mismatch-repair genes 
MHS2, which constitutes the phototype of mismatch-repair genes. It is actually thought that 
this may trigger microsatellite instability, thus contributing to the development of UV 
related skin tumors. In a previous study, we have shown also in oral melanomas that a 
deregulating expression of both hMSH2 and hMLH1 (mut L homologue 1) occurs. hMLH1 
is frequently silenced in tumors with microsatellite instability. Both these genes can actually 
predispose to mutational events during tumor progression. We hypothesized that the 
altered expression of both HMSH2 and hMLH1 contributes to the mutagenic effect of UVR 
on melanocytes and, in turn, may be also involved in  melanoma resistance to DNA 
damaging agents (Lo Muzio et al., 2000; Staibano et al., 2001). 
2.2 BRAF 
Alteration of the RAF/MEK/ERK pathway influences proliferation, invasion and survival 
of melanoma cells in vitro. For this reason it emerges then that B-Raf mutation has a pivotal 
role in determining melanoma biology, even if its exact function in melanoma progression 
remains still controversial. BRAF is a serine/threonine kinase that signals downstream of 
RTKs and RAS protein. Point mutations of B-Raf alter its auto-regulatory activation (Rother 
& Jones, 2009). The frequency of B-Raf mutations in melanoma and nevi is really impressive, 
being detectable in 30 to 80% of cases. Very interestingly, melanomas have a BRAF 
mutational spectrum different from other tumours, this probably reflecting the UVR 
environmental exposure (Thomas et al., 2006). This idea is further supported by the frequent 
occurrence of these mutations in SSM or NM of intermittently sun-exposed skin and in 
younger patients, whereas they are rare in AM (5-10%) and non-cutaneous melanomas 
(Platz et al., 2008). Over 30 distinct BRAF mutations, varying in biological activity, have 
been found and may be predictive of clinically relevant tumour differences (Thomas et al., 
2006). The most common is constituted by a glutamic acid (glu) for valine (val) substitution 
at residue 599 (V600E) in the activation segment. At present, in spite of all these technical 
information, we are far away to the understanding of the real meaning of BRAF mutation in 
melanoma. It seems to correlate with distinct histopathologic features, such as 
intraepidermal “pagetoid” spreading of cohesive nests of malignant melanocytes, and 
“pushing” rather than infiltrative border of the tumor, as well as with the younger age and 
lymph node metastasis at diagnosis (Rother & Jones, 2009). However, these hypotheses 
show considerable inconsistencies, if we consider that benign nevi show even higher rates of 
V600E BRAF mutation and cell line or transgenic mouse models of melanoma have failed to 
unequivocally demonstrate the transforming ability of this mutation (Rother J et al, 2009). 
Recently, Dhomen N et al. have developed a mouse model of BRAFv600E-driven 
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melanoma, showing that V600E BRAF mutation alone stimulates proliferation of 
melanocytes but cannot induce full transformation, which presumably requires the 
acquisition of additional mutations (Dhomen N, et al., 2009). Nevertheless, the BRAFV600E 
has evolved into the most important target in melanoma. First-generation non-selective RAF 
inhibitor (Sorafenib) as a single therapy or in combination with carboplatin and paclitaxel 
(Hauschild et al., 2009), iinhibitors of the MAPK pathways with activity for either BRAF or 
MEK (as PLX4032, Flaherty et al., 2010), induction of specific cellular immunity against 
BRAFV600E, BRAFV600E inhibitors based on the crystal structure of BRAFV600E complexes, are 
providing conflicting results in patients with metastatic melanoma. New potent small 
molecule inhibitors of mutant BRAF, combined to the immunotherapy agent ipilimumab 
have demonstrated promising clinical activity. However, despite initial high response rates, 
in most cases these results persist for a short time and melanomas recur after a few months, 
showing resistance to the previously effective B-RAFv600E inhibitors (Nazarian et al., 2010; 
Villanueva et al., 2010). One invoked mechanism which can influence the clinical response 
to antineoplastic therapy could be the pharmacogenomic variation in both the tumor and 
the patient's genome (Wang et al., 2011). Recently, high-throughput screening methods have 
been proposed to uncover the mechanisms of resistance in these tumors (Garraway, 2010). 
However, further studies on B-RAF mutant melanomas are needed before definitive results 
will be reached. A recent genome-wide RNA-interference screening targeting 28,000 genes, 
identified 17 genes able to block uncontrolled proliferation of melanocytes in the presence of 
BRAFV600E, among them a relevant role seems to be played by IGFBP7 (insulin-like growth 
factor binding protein 7 ), which is often epigenetically silenced in primary melanomas. The 
functional relevance of these genes in human melanoma remains unclear.  Overall, it seems 
evident that several mechanisms act together during malignant transformation and 
progression of melanoma. Activating or inactivating mutations of members of the Akt 
signalling pathway (phosphatidylinositol 3-kinase CA, PI3KCA and Akt kinase) and 
mutations of tumor suppressor phosphatase and tensin homolog (PTEN) are frequently 
found in melanomas. Hopefully, targeting these molecular pathways will change the 
standard of care of metastatic melanoma in the future, but further studies focused on 
identifying predictors of chemotherapeutic response are needed. 
2.3 PTEN/AKT 
PTEN is a phosphatase that acts as a tumor suppressor gene, regulating the activation of the 
global regulators of cell proliferation serine/theronine kinases AKT1/2-3. Complete PTEN 
loss (usually due to genomic deletion) is found in 20-25% of melanomas, sometimes in 
combination with BRAF mutation, and leads to high-level AKT activation (Rother & Jones, 
2009). Rare activating mutations of the AKT1 or AKT3 isoforms have been found in sun-
exposed melanoma subtypes. Moreover, AKT overexpression may be associated with 
melanoma growth in situ. 
2.4 Timing of melanoma progression 
The central theme of melanoma research actually focuses on changes in gene expression 
occurring at the RGP/VGP shifting. We are now in a conceptual transition phase, in which 
the Clark model of neoplastic progression of melanocytes is being questioned. Basing upon 
the growing body of molecular data and considering the finding that many melanomas arise 
de novo on normal skin instead of from pre-exsisting melanocytic nevi, the biology of 
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melanocytic lineage could be examined from a point-of-view alternative to the postulated 
classical Clark model. This latter postulated that melanoma derives from (Takata et al., 2009) 
benign melanocytic nevus, which usually temporarily undergoes proliferation via oncogenic 
BRAF signalling, followed by growth arrest due to senescence induced by p16INK4/Rb. 
When a disruption of p16INK4a-retinoblastoma (Rb) pathway occurs, mostly by the 
inactivation of CDKN2A, the nevus become “dysplastic” and progressively more atypical, 
up to the RGP melanoma. At this stage, melanoma cells are dependent on growth factors 
secreted from keratinocytes, such as endothelin-1 (Murata et al., 2007), and are immortal, 
due to the activation of human telomerase reverse transcriptase (hTERT). In the vertical 
growth phase (VGP), mutations repressing apoptosis and favouring invasion (as PTEN loss, 
RAS activation, b-catenin activation) allow neoplastic melanocytes to survive in the absence 
of keratinocytes (Bennett 2003).  
According to this theory, the interaction between melanoma cells and stromal fibroblasts 
further promotes tumor growth, migration, and angiogenesis (Li et al. 2003), but recently it 
has been proposed to revise this model of neoplastic progression of melanocytes, basing on 
the same evidences. Firstly, melanocytic nevi often consist of polyclonal population of either 
wild-type BRAF and BRAF mutated-nevus cells; moreover as before mentioned, many 
melanomas arise de novo (Takata et al., 2009). The p16INK4a-Rb inactivation (by deletion, 
mutation or promoter methylation of the CDKN2A gene, amplification of CCND1 or CDK4, 
or Rb mutation) (Bennett, 2008) has been demonstrated in early RGP melanomas (Takata et 
al., 2009), which in turn acquire a proliferative mutation, such as BRAFV600E, and clonally 
proliferate, maintaining a minimum telomere length through activation of hTERT. The full 
oncogenic transformation to VGP melanoma requires additional genetic or epigenetic 
changes, suppressing apoptosis, altering cell-cell adhesion, and leading to 
hyperproliferation and stromal invasion, for example via up-regulation of genes coding for 
cell surface and secreted proteins, as Neuropilin-2 (NRP2), which plays a critical role in 
mediating melanoma-endothelial interactions (Stine et al., 2011). 
2.5 HIF1/ROS and melanoma-microenvironment 
ROS are mutagenic molecules. Most of apoptosis regulators are known to be potentially 
mutated or functionally altered by ROS: BRAF (RAS, MEK, and ERK within the MAPK 
pathway), PTEN, Rb and AKT (Wittgen & van Kempen, 2007; Fruehauf & Trapp, 2008). 
Melanoma cells generate large intracellular amounts of ROS (Sander et al., 2003) and excrete 
them into the extra cellular space. An upgraded ROS production has also been observed in 
dysplastic nevi (Pavel et al., 2004). ROS emerging as bio product during physiological 
melanin synthesis are neutralized within melanosomes by the anti-oxidant melanin. 
Melanosomes of malignant melanocytes produce excessive amounts of ROS (Gidanian et al., 
2008; Josse et al., 2010) and in addition produce, instead of the regular eumelanin, 
pheomelanin, which is associated with more oxidative stress. In view of these unique 
melanoma properties, elevated production of ROS seems to be a melanoma- specific defect 
(Fruehauf and Trapp, 2008). Other factors may contribute to elevate ROS levels around the 
primary tumor: the skin is a hypoxic tissue, leading to ROS production (Wittgen & van 
Kempen, 2007) and exogenous attacks (e.g. UV-radiation) further increase oxidative stress. 
In addition, tumor-associated immune cells also excrete ROS (Nishikawa, 2008). Reactive 
oxygen species derived from immune cells have been proposed to exert a ‘selective 
pressure’ on MM cells to develop ROS-resistance (Wittgen & van Kempen, 2007). Following 
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this hypothesis, the entire ‘ROS-saturated environment’ in and around the primary tumor 
may exert a selective pressure on MM cells, causing the selection of those with the highest 
ROS resistance, whereas unfit cells die of ROS-induced apoptosis. After acquiring ROS 
resistance to block apoptosis, MM cells can also use high ROS levels to further stimulate 
their metastatic potential (Nishikawa and Hashida, 2006) through an impressive variety of 
pathways; from induction of DNA changes and activation of cell proliferation, to 
destruction of surrounding tissue, induction of adhesion molecules, activation of metastatic 
processes and escaping immune surveillance. In summary, ROS act as pro-metastatic agents 
through a wide range of pathways (Josse et al., 2010), which in melanoma cells accumulates 
early in tumor progression due to the alteration of melanin produced by characteristically 
abnormal melanosomes (Fruehauf & Trapp, 2008; Meyskens, 2001; Gidanian et al., 2008). 
HIF-1 activity is highly regulated by hydroxyl radicals and other reactive oxygen species 
(ROS) (Kietzmann & Gorlach, 2005; Wittgen & van Kempen, 2007, Kuphal et al., 2010) HIF-1 
molecular complex is the major transcriptional regulator of the cellular and systemic 
response to a hypoxic environment, and is involved in cancerogenesis, regulating the 
expression of factors fundamental for angiogenesis (VEGF) and tumour invasion (glycolytic 
enzymes) (Forsythe et al., 1996; Wenger, 2002; Wiesener & Maxwell, 2003; Erler et al., 2006). 
HIF-1 contributes also to the induction of vasculogenic mimicry (Sun et al., 2007). In 
melanoma cells HIF-1 expression is also regulated both at the translational and 
transcriptional level by various other molecular ways, comprising the 
AKT/phosphatidylinositol 3-kinase (PI3K) pathway, (Jiang et al., 2001) enhanced by the 
hypoxic skin environment, and by V600E BRAF (Minet et al., 2000; Galabova-Kovacs et al., 
2006) and the transcription factor NFkappaB (Bonello et al., 2007, Rius et al., 2008). This 
latter, in turn, is constitutively upregulated in melanoma cell lines (Kuphal et al., 2004) and, 
in addition, may be regulated by ROS and/or JNK, either induced by UVR or directly 
triggered by the activation of the RAS/RAF/MEK pathway (Tobar et al., 2008; Bonello et al., 
2007; Li & Karin, 1999; Kuphal et al., 2010). HIF-1 activity is modulated also by mTOR. In 
particular, it has been shown that downregulation of HIF-1 by the mTOR inhibitor 
rapamycin prevents transformation under hypoxia, this suggesting that Rapamycin may be 
proposed as a therapeutic approach in melanoma treatment (Bedogni et al., 2005; Michaylira 
& Nakagawa, 2006). This is of particular interest, considering that Rapamicin has been 
shown to stimulate apoptosis in melanoma cell lines through the specific inhibition of 
FK506-binding protein 51 (FKBP51) isomerase activity (Romano et al., 2004).This protein 
belongs to a family of immunophilins physiologically expressed in lymphocytes, involved in 
the regulation of several fundamental biological processes and over-expressed in cancers 
and premalignant lesions. FKBP51 has been associated to the apoptosis resistance of 
malignant melanoma. In a recent study, we demonstrated that the expression of FKBP51 is 
markedly increased in vertical growth phase of melanomas and in metastatic lesions, 
providing evidence that FKBP51 is a marker of melanocyte malignancy (Romano et al., 
2010a, 2010b). In addition we found that FKBP51 is a factor of resistance to genotoxic agents, 
including anthracyclins and ionizing radiations, through NF-kB activation. 
2.6 cKIT 
KIT encodes a receptor tyrosine kinase (RTK), which is recognized as a ligand for a stem cell 
factor (SCF) (Takata et al., 2009). Dysregulation of KIT plays a role in systemic mastocytosis, 
acute myelogenous leukaemia, gastrointestinal stromal cell tumors (GISTs) and germ cell 
tumors (Patnaik et al., 2007). A critical role for c-Kit for normal neural crest and normal 
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melanocyte development, (Rother & Jones, 2009) differentiation, proliferation, survival and 
migration (Wehrle-Haller, 2003) has been recognized, but its function in melanoma remains 
somewhat unclear. As a rule, c-Kit expression is lost during melanoma progression, but a 
subset of melanomas has been found to overexpress it and mutations activating c-Kit, 
mostly constituted by L576P (up to 50% of mutations), have recently been identified in some 
mucosal and AL melanoma subtypes (5-20% of cases), but not in cases arising from chronic 
sun-damaged skin (Rother & Jones, 2009; Monsel et al., 2010). KIT is expressed at maximum 
level at the invading edge of tumors, this suggesting a role for dynamic RTK activation in 
metastasis (Handolias et al., 2010). Monsel et al (Monsel et al., 2010) demonstrated that c-Kit 
mutated melanocytes require a specific epigenetic environment to be transformed in 
melanoma cells. c-Kit mutants cause in fact a strong activation of the phosphatidyl-inositol-3 
kinase (PI3K) pathway, which, per se, is not sufficient to promote transformation of 
melanocytes. However, in the chronic hypoxic skin microenvironment, and/or when a 
constitutively active form of hypoxia-inducible factor 1alpha (HIF-1alpha) is coexpressed, c-
Kit mutants activate also the Ras/Raf/Mek/Erk pathway, transforming the melanocytes, 
(Monsel et al., 2010). This scenario is extremely interesting, considering that KIT mutations 
are mutually exclusive with BRAF and NRAS, to identify a subset of melanomas arising 
from a distinct molecular mechanism of transformation, which may be specifically targeted 
by KIT inhibitors, such as imatinib or sorafenib (Monsel et al., 2010).  
2.7 Plexin B1 
Plexin B1 interacts with small G proteins to regulate cell proliferation, migration, and 
apoptosis, and is repressed by oncogenic B-RAF signalling; its loss of expression in vivo has 
been documented in breast cancer and renal cell carcinoma (Stevens et al., 2010). Plexin B1 
functions as a tumor suppressor in melanoma cells, as it has been recently shown in a mouse 
model (Stevens et al., 2010; Argast et al., 2009). Introduction of plexin B1 into melanoma cell 
lines suppresses tumor formation in mice (Rody et al., 2009; Gomez Roman et al., 2008; 
Argast et al., 2009), this being thought to be due, at least in part, to suppression of c-Met 
signalling and c-Met-dependent migration. Recently, it has been evidenced that plexin B1 is 
lost in metastatic and deeply invasive melanoma in patient samples in vivo (Stevens et al., 
2010), whereas it is generally hyperexpressed in benign nevi and thin melanomas. This 
finding suggests that the loss of plexin B1 contributes to late stages of melanoma 
progression, including invasion and metastasis. Recent evidences indicate that plexin B1 can 
also activates the PI3-kinase-Akt pathway, thus functioning as a tumor promoter and 
inhibitor of apoptosis in melanomas not driven by c-Met activation (Stevens et al., 2010). 
These results require further investigation. If confirmed, they could indicate that the final 
action of plexin B1 on melanoma progression may depend on the balance between c-Met 
receptor blockade and the interaction of plexin B1 receptor to downstream targets 
independent of c-Met signalling, such as Akt.  
2.8 Tumor-stromal interactions 
Mutant BRAF melanomas show high levels of constitutively activated Erk 1,2 (Houben et 
al., 2004). Consequences of Erk 1,2 pathway activation include induction of cell proliferation, 
expression of melanoma transcription factors, matrix metalloproteinases, specific integrin 
subunits, and resistance to apoptosis (Rubinstein et al., 2010). Melanoma chondroitin sulfate 
proteoglycan (MCSP) is a plasma membrane-associated proteoglycan which interacts with 
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distinct Erk-binding sites (Yang et al., 2009). As for Erk 1,2, its functions range from 
remodelling tumor microenvironments, facilitating the growth, invasion and motility of 
tumor cells to modify the organization of the cytoskeleton by modulating the activity of Rho 
family. Normal melanocytes express little or no MCSP, while the protein expression 
increases from benign and dysplastic nevi (Campoli et al., 2004) to melanoma. In RGP 
melanoma, MCSP expression enhances integrin function and constitutive activation of Erk 
1,2. As already shown in acral lentiginous melanoma (such as in acute lymphoblastic 
leukaemia) MCSP expression is thought to be associated with a poor prognosis (Kageshita et 
al., 1991). These evidences indicate that MCSP, as a member of the Erk 1,2 pathway, may be 
considered as a promising therapeutic target in the treatment of melanoma. 
3. Epigenetics 
Epigenetics refers to changes in phenotype or gene expression without alterations of the 
DNA sequence. These changes occur at a much higher frequency compared to gene 
mutation, and may persist for the entire cell life and even for multiple generations (Kyrgidis 
et al., 2010). These “epimutations”allow the cell to modulate the transcriptional activity of a 
given gene, from high-level expression to complete silencing. Transcription results from the 
activity of the RNA polymerase machinery and depends on the ability of transcription 
activators and repressors to access chromatin at specific promoters (Santos-Rosa & Caldas, 
2005). Chromatin is the dynamic scenario in which all the genomic functions take place; its 
structure is governed by the interplay of complex regulatory systems, which guarantee the 
maintenance of higher order chromosomal organization. Our understanding of how 
modulation of chromatin influences cell fate in normal as in neoplastic cells has been greatly 
improved during the last two decades. DNA replication, repair and transcription are 
achieved through the interplay of DNA modification and alteration in DNA packaging 
(Rountree et al., 2001). These mechanisms cooperate to establish the pattern of gene 
expression (Hashimshony et al., 2003) concerning every fundamental cell function, from cell 
growth and differentiation, to DNA repair and apoptosis. They operate through the 
induction of changes in chromatin architecture induced by histones (Dong & Bode, 2006) 
and “chromatin modifiers” (Kyrgidis et al., 2010). Histones are the main protein components 
of chromatin. Covalent post-translational modifications of the amino termini of the core 
histones in nucleosomes consist of methylation, acetylation, phosphorylation, ubiquitination 
and SUMOylation, and determine the “histone code” (Berger, 2002). 
3.1 DNA methylation 
DNA methylation occurs on lysine and arginine residues on histone tails. One preferred site 
of methylation is the C5 position of cytosine in the context of CpG dinucleotides. The latter 
may be found throughout the genome but are frequently clustered in short regions of 0.5–
4kb, known as CpG islands (Bird, 2002), mostly located at the promoter regions of genes and 
unmethylated in normal cells. Hypermethylation of these regions causes the “silencing” of 
the target gene. DNA methylation is carried out by different DNA methyltransferases 
(DNMT) that use s-adenosyl-methionine as a methyl donor to replace a hydrogen atom with 
a methyl group (Board et al., 2008) and have distinct substrate specificities: DNMT1 
(Pradhan et al., 1999), DNMT3a and 3b (Okano et al., 1999). All these DNMTs cooperate in 
establishing and maintaining DNA methylation patterns (Rhee et al., 2000; Kim et al., 2002). 
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In normal cells, methylation of CpG sites within promoter regions is used for controlling 
gene expression (Klose & Bird, 2006). In cancer cells, hypermethylation of the promoter 
regions of growth-regulatory genes leads to transcriptional silencing (Eden et al., 2003; Bonazzi 
et al., 2009), whereas hypo/demethylation results in de-repression of proto-oncogenes and 
genome wide hypomethylation leads to increased mutation rates and chromosome instability, 
which constitutes an early hallmark of tumour cells (Feinberg et al. 2002; Robertson, 2005; 
Martinez et al., 2009). The peculiar changes in DNA methylation patterns of human cancers 
are commonly constituted by reduced levels of DNA methylation and aberrantly 
hypermethylated CpG islands (Bird, 2002), which has been termed “the CpG island 
methylator phenotype” (CIMP) (Board et al., 2008). In cancer, epigenetic silencing through 
methylation occurs at even greater frequency than mutations or deletions and may be a 
more frequent cause of loss of function of tumor-suppressor genes than genetic defects (Jones 
& Baylin, 2002; Herman, 1999), suggesting that epigenetic changes have a major role in every 
step of tumor progression (Baylin, 2005). The genes that are known to be frequently 
hypermethylated and silenced in cancers frequently reside in chromosome regions that 
commonly show loss of heterozygosity, and their loss-of-function provides a selective growth 
advantage to neoplastic cells, and/or are implicated in tumor metastasis and angiogenesis 
(Baylin, 2005). Among these genes, we found most of them frequently mutated in cancers, as: 
ATM, ataxia telangiectasia mutated; APC, adenomatosis polyposis coli; BRCA1/2, breast 
cancer1/2; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; GSTP1, glutathione S-
transferase pi; MLH1, mutL homologue 1, colon cancer, non-polyposis type 2; MSH2, mutS 
homologue 2, colon cancer, non-polyposis type 1; NF12PTCHPTEN, phosphatase and tensin 
homologue; RB1, retinoblastoma 1; SWI/SNF-related, matrix-associated, actin-dependent 
regulator of chromatin, subfamily A, member 3/subfamily B, member 1; TIMP3, tissue 
inhibitor of metalloproteinase 3; TP53/73, tumour protein p53/p73. 
3.2 Histone acetylation 
In an opposite manner respect to methylation, acetylation of histones reduces the positive 
charge, relaxing chromatin and making DNA in a transcriptionally active state, mediated 
mainly by the binding of transcriptional factors and histone acetylates. By a simplified 
point-of-view, we can assume that hyper acetylated histones are mostly associated with 
activated genomic regions, whereas deacetylation/hypoacetylation results in 
repression/silencing. In addition, histone acetylation allows also the binding of some 
regulatory transcriptional co-activators (Baylin, 2005), as the SWI/SNF adenosine 
triphosphatase (ATP)-dependent chromatin remodelling complex. Chromatin remodelling 
complex (“chromatin modifiers”) is large protein complexes with enzymatic activity able to 
modify the structure and transcriptional activity of the chromatin. In an indirect manner, 
then, histone acetylation cooperates also to the regulation of gene expression mediated by 
the modification of higher-order chromatin folding (Verdone et al., 2006). 
3.3 Phosphorylation 
Other chromatin modifications, in concert with DNA methylation and acetylation, regulate 
gene transcription, in normal as in cancer cells, by affecting local chromatin structure. One 
of these modifications is constituted by phosphorylation of serines and threonines (Dong & 
Bode, 2006). Berger (Berger, 2002) showed that phosphorylation of histone (Ser10) is 
fundamental for neoplastic cell transformation. 
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3.4 Ubiquitination and SUMOylation 
The other histone post-translational modifications include ubiquitination and SUMOylation. 
Ubiquitin is a highly conserved protein associated with most of fundamental cellular 
processes and its deregulated activity is thought to contribute to cancer onset or 
progression.  SUMOylation directly affects nucleosomal structure, but the exact molecular 
mechanism is still not clear (Gill, 2004). Recently it has been shown that histone H4 is 
modified by SUMO, and SUMO-modification of histones has been suggested to contribute 
to transcriptional repression (Shiio & Eisenman, 2003), regulation of protein–protein 
interactions and activity of many factors involved in maintenance of the genome stability. 
Many factors and enzymes associated with DNA replication and repair including PCNA, 
and Topoisomerases I and II, are post-translationally modified by SUMO (Muller et al., 
2004). The activity and/or localization of several tumor supressors and oncogenes are 
regulated by SUMO modification, and this has been hypothesized to provide new chances 
for new target therapy for cancer (Gill, 2004). 
3.5 Interplay between different post-translational modifications 
It has to be pointed out that single histone modifications may have distinct biological effects 
depending on their context. Methylation of H3 on K9, for example, is largely associated with 
silencing and repression. Methylation of lysine 9 on histone H3 is associated with 
epigenetically silenced chromatin, and loss of the H3K9me3 mark results in genomic instability 
(Cloos et al., 2006). Methylation of H3 on K4, by reverse, is most often associated with active or 
permissive chromatin regions. Moreover, demethylation of H3-K4 occurs at both inactive and 
active euchromatic genes, whereas tri-methylation is present exclusively at active genes. 
Similarly, the phosphorylation of H3 at S10 has been implicated not only in transcriptional 
activation, but also in mitotic chromosome condensation. This led to the suggestion that 
multiple readouts of a certain covalent mark could be obtained by various combinations of 
different modifications in the same chromatin region. Particular sets of modifications might 
occur concomitantly on the same histone tail. Mounting evidence suggests that different 
histone modifications can influence or ‘communicate’ with each other at several levels (Fischle 
et al., 2003). Moreover, as a rule, histone acetylation/deacetylation and methylation operate 
synergistically in cancer cells (Rountree et al., 2001), but competition for lysines may create 
crosstalk between SUMO and other modifiers. Acetylation may enhance SUMOylation of 
histone H4 (Gill, 2004); HATs and HDACs (that respectively add and remove acetyl groups) 
are post-translationally modified by SUMO, which regulates also their localization and/or 
activity (Girdwood et al., 2003). Cross-talk between the SUMOylation, ubiquitination, and 
acetylation occurs during signal-dependent regulation of several proteins (Hoege et al., 2002; 
Ross et al., 2002). From these data it emerges that the epigenetic framework which regulates 
gene expression is an extremely complex process, constituted by a multitude of intersecting 
molecular factors converging on chromatin. 
3.6 miRNA 
MicroRNAs (miRNAs) are recently discovered endogenous non-coding RNAs, about 22 
nucleotide long (Guil & Esteller, 2009; Sigalotti et al., 2010). They play a role as mediators of 
epigenetic gene regulation, by interacting with mRNA, either by inhibiting mRNA 
translation or causing mRNA degradation (Sood et al., 2006). Their regulatory nature, as 
well as the large number of presumptive target genes, candidate them as regulators of 
several fundamental cellular processes, in normal as in cancer cells. 
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3.7 Melanoma epigenetics 
3.7.1 Methylation 
At present, it is not clear if UVR can initiate melanomagenesis through an epigenetic 
mechanism. Nevertheless, epigenetic changes, as mutations, increase after ultraviolet 
radiation (UVR) (Kyrgidis et al., 2010). This is of a great interest, considering that 
intermittent, intense exposure to UVR, especially during childhood, is major environmental 
risk factor in the etiology of melanoma (Maddodi & Setaluri, 2008). Deregulation of gene 
expression in melanoma progression requires epigenetic mechanisms which are currently 
uncompletely characterized, but  have a potential great impact on the process of melanoma 
tumorigenesis and metastatic potential (Howell et al., 2009; Schinke et al., 2010). To date, 
more than 50 genes have been shown to be silenced through epigenetic changes during 
melanoma development, progression, and metastasis, mainly by promoter CpG island 
hypermethylation (Rothhammer & Bosserhoff, 2007; Howell et al., 2009), as it has been 
reported for MAGEA1 (Karpf et al.,2004). Most of these genes are not specific for melanoma, 
being involved in the control of cell cycle, cell signalling, immune recognition, angiogenesis, 
apoptosis, tumor cell invasion and metastasis in almost all cancer types (Rothhammer & 
Bosserhoff, 2007). Among these, there are CDKN2A, PTEN, APAF-1, TPM1 and TIMP3, 
several human leukocyte class I antigens and CASP8. Recently, have been found methylated 
in melanoma other genes linked to apoptosis (DAPKb, HSPB6, HSPB8, TMS1, TP53INP1, 
TRAILR1, XAF1), anchorage-independent growth (TPM1; cell cycle: CDKN1B, CDKN1C, 
CDKN2A, TSPY); chromatin remodeling (NPM2); differentiation (HOXB13, ENC1, GDF15); 
DNA repair (MGMT); invasion/metastasis (CCR7, CXCR4, SERPINB5); signaling 
(PGRbeta); transcription (RUNX3) (Sigalotti et al., 2010). In several cases, these aberrant 
hyper-methylations are recognizable in an high percentage of melanomas, as for 
Suppressors of cytokine signaling SOCS-1 (75%), SOCS-2 (75%),  SOCS-3 (60%) (Liu et al., 
2008), ER-ǂ Estrogen receptor alpha (42%–86%) (Mori et al., 2006), p101(PIK3R5) 
Phosphoinositide-3-kinase, regulatory subunit 5 (88%), TNFRSF10C (DcR1) Tumor necrosis 
factor receptor superfamily, member 10c (55%) and TNFRSF10D (8 5%) (Liu et al., 2008), 
THBS4 Thrombospondin 4 (63%), RASSF1A RAS association domain family protein 1A 
(involved in apoptosis: its expression negatively correlates with lymph node metastasis, 
55%), (Yi et al., 2010), HSP11, Heat shock protein H11 (60%), and RARǃ2, Retinoic acid 
receptor, beta isoform 2 (70%, linked to the low retinoid sensitivity of melanoma) (Hoon et 
al., 2004). Up to 100% of melanoma cases show hyper-methylated CYP1B1 (Cytochrome 
P450, subfamily 1, polypeptide 1, linked to drug metabolism) and QPCT (Glutaminyl-
peptide cyclotransferase) (Muthusamy et al., 2006). Recently, in cutaneous melanoma the 
loss of expression/methylation of gene promoter for Tumor suppressor in lung cancer 1 
(TSLC1), encoding a member of the immunoglobulin superfamily, has been described (You 
et al., 2010). In some cancer types, this phenomenon leads to poor prognosis, and in 
melanoma it is significantly associated with advanced tumor stage and shorter disease-
related survival, thus appearing as an important event in the pathogenesis of CM and a 
marker of poor prognosis (You et al., 2010). Similarly, recent findings indicated that a 
frequently aberrant methylated region in CM resides within the Zygote arrest 1 (ZAR1) 
gene, demonstrating a distinct methylation pattern between melanoma and nevus, thus 
hypothesizing that the aberrant methylation of ZAR1 may be a useful tumor biomarker to 
distinguish nevus from melanoma for early diagnosis (Shinojima et al., 2010). As well, there 
is an increasing body of evidence that, indicating the inactivation of the dimeric 14-3-3σ 
proteins member of the oncogene RAS/RAF/MEK/Erk pathway, involved in DNA damage 
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repair or arrest of cell cycle after severe damage, plays an important role in primary melanoma 
development. This has been reported for several malignant tumors (Schultz et al., 2009). 
Moreover, enhanced 14-3-3σ gene methylation in lymph node and cutaneous melanoma 
metastases compared with primary tumors was associated with significant 14-3-3σ 
downregulation. Treatment of melanoma cells with methylation and histone deacetylase 
inhibitors has led to the increase of 14-3-3σ expression, inhibition of cell proliferation, and 
induction of melanoma cell senescence. Epigenetic profiling showed, in addition, that multiple 
metastases after a single primary melanoma either share similar methylation patterns for 
many genes, or show differences in methylation between the lesions for several genes, as for 
PTEN, TFAP2C, and RARB (Harbst et al., 2010). Less is known on the presence and role of 
demethylation in CM, this reflecting the state-of-the art of the research on genome-wide 
demethylation in cancer, which has been overshadowed, to date, by studies of gene-specific 
hypermethylation events. It is generally thought that global demethylation early in 
tumorigenesis might predispose cells to genomic instability and further genetic changes, 
whereas gene-specific demethylation frequently constitutes a later event that favours the 
establishment of metastasis (Robertson, 2005). Recent study report that MAGE-A1, A2, A3, A4, 
which are involved in immune recognition and belong to the melanoma antigen family of 
cancer–testis genes, encoding tumour antigens of mostly unknown function,  are frequently 
demethylated and re-expressed in cancer (Robertson, 2005) and hypomethylated in 44% of CM 
(MAGEA1) (Sigalotti et al., 2010; Tellez et al., 2009). This is very interesting, if we consider that 
the same family of genes, as before reported, may be found frequently hypermethylated in 
melanoma. This is also the case for the Testis-specific protein, Y-encoded (TSPY) (Oram et al., 
2006; Howell et al., 2009), and maspin, a mammary serine protease inhibitor, acting as a TSG in 
breast cancer (Wada et al., 2004) that is repressed in normal melanocytes. 
3.7.2 Phosphorylation 
Phosphorylation of histone H3 at serine 28 and 10 is strongly induced by UV irradiation 
(Dong et al., 2006), and is mediated by the MAP kinase cascades (Zhong SP et al., 2000). 
UVA and UVB differentially induce the MAP kinase pathways at different levels (Bode & 
Dong, 2003): ERKs and p38 kinase mediate UVB-induced H3 (Ser10) phosphorylation in 
mouse epidermal skin cells and in vitro. It has been hypothesized that the p53 protein may 
directly regulate this phosphorylation by serving as a link or a bridge between these kinases 
and histone H3. Moreover, it has been found that also (He Z et al., 2005). Fyn, a member of 
the Src kinase family, and Aurora B kinase overexpression are involved in the UVB-induced 
phosphorylation of histone H3 (Ser10) (Ota et al., 2002). Recent data suggest that H3 histone 
phosphorylation plays a role in UV-mediated carcinogenesis. 
3.7.3 Acetylation 
Three members of the HATs family, the transcriptional coactivators, GNAT (general control 
non-depressible 5 (Gcn5)-related N-acetyltransferase), MYST (family members: MOZ, Ybf2-
Sas3, Sas2, and Tip60) and p300/CBP-adenoviral E1A-associated protein, 300 kDa, (CREB-
binding protein), have been recently found linked to melanoma progression. Members of the 
GNAT family (including GCN5, HAT1) and PCAF (p300/CREB-binding associated factor) 
acetylate histones H3 and H4 and non-histone transcriptional activators. P300 and CBP are 
global transcription coactivators that acetylate core histones and non-histone proteins such as 
p53, Rb, and E2F, involved in regulation of cellular proliferation, differentiation and apoptosis 
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(Shiama et al., 1997). Both CBP and p300 have been also shown to associate with 
microphthalmia-associated transcription factor (MITF), a melanocyte lineage survival 
oncogene (Garraway et al., 2005), which regulates melanoma proliferation, apoptosis and 
invasiveness (Dynek et al., 2008), and is mostly upregulated in metastatic melanomas (Lomas 
et al., 2008) being associated with decreased survival of patients (Ugurel et al., 2007). 
3.7.4 Ubiquitination/SUMOylation 
Accumulating evidence confirms the involvement of ubiquitin and ubiquitin–related 
pathways in melanomagenesis. Transcription factors such as MiTF, beta-catenin and IkB, 
which regulate the proliferation and differentiation of melanocytes, are subjected to this 
process (Wu et al., 2000). In normal melanocytes, MITF may be in turn subjected to 
ubiquitination or SUMOylation. In melanoma, ubiquitination leads to the corresponding 
elevated activity of MITF (Nakayama, 2010). In addition, melanoma cells show an alterated 
ubiquitination-dependent degradation of IKB, with consequent high rate of nuclear 
translocation of free NF-kB and activation of its target genes (Nakayama, 2010). Notably, 
also B-catenin is a target of the ubiquitin–proteasome pathway in melanoma. Several beta-
catenin mutants lack sites of ubiquitination and, consequently, become stabilized because of 
the inhibition of proteasome-mediated proteolysis; thus promoting proliferation and 
survival of melanoma cells (Aberle et al., 2007; Rubinfeld et al., 1997; Widlund et al., 2002). 
3.7.5 Chromatin texture 
The neoplastic growth-induced modification of composition and distribution of histone and 
non-histone nuclear proteins provokes alterations of the distribution of heterochromatin in the 
nucleus. This reflects on the characteristics of the nuclear architecture, as seen on routinely 
stained histopathological sections, and has suggested as prognostic markers in cancer 
(Montironi et al., 2007). The determination of fractality characterizes the complexity of a 
structure not revealed by classical morphometry. The fractal nature of nuclear chromatin and 
of the surrounding nucleoplasmic space (Lieberman-Aiden et al., 2009; Bancaud A et al., 2009) 
are of prognostic importance in neoplasias (Goutzanis et al., 2008; Mashiah et al., 2008). 
Unstable, aggressive tumors with a high number of genetic or epigenetic changes, are 
characterized by a complex chromatin rearrangement, with an increased number of darker 
and lighter areas. The increased nuclear fractal dimension found in the most aggressive 
melanomas is the mathematical equivalent of this complex chromatin architecture, 
constituting a new and promising variable in prognostic models (Bedin et al., 2010), able to 
provide prognostic information independent from the invasion level of melanomas.  
3.7.6 Chromatin assembly 
Nuclear structure and function interact reciprocally at all the three hierarchical nuclear 
levels (coordination of nuclear processes, higher-order chromatin fiber organization, and 
spatial arrangement of genome) (Misteli, 2007). The chromatin template undergoes 
structural reorganizations during DNA replication and cell cycle progression (Fischle et al., 
2003). Nucleosomes, made of 146 base pairs of DNA wrapped around a histone octamer 
core comprising two copies each of histones H2A, H2B, H3 and H4, represent the basic 
functional units of chromatin. Each histone contains flexible N-terminal tails protruding 
from the nucleosomes, which are extensively targeted by post-translational modifications, 
including acetylation and methylation (Sigalotti et al., 2010). When in open configuration, 
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they allow access of transcription factors. By converse, when they are in a hyper-compacted 
state, as in heterochromatin, inhibit transcription (Jones & Baylin, 2002; Jenuwein & Allis, 
2001; Noma et al., 2001). Nucleosome structure and histone acetylation/methylation equally 
affect chromatin structure, regulating gene transcription (Baylin, 2005). Among molecules 
responsible of the chromatin assembly, a pivotal role is exerted by the Chromatin Assembly 
Factor-1 (CAF-1), a protein complex, formed of three subunits with different molecular 
weight: p48, p60 and p150. CAF-1 deliveres histones H3 and H4 to DNA during DNA 
replication and DNA repair, and CAF-1/p60 has been found overexpressed in a series of 
human malignancies, including breast, prostate, oral squamous and salivary glands cancers, 
in close association with their biological aggressiveness. We have evaluated by 
immunohistochemistry the expression of CAF-1/p60 in a selected series of cutaneous 
melanomas paraffinized tissue (Mascolo et al., 2010), comparing results with the clinical and 
pathological features of each tumor and with patient’s outcome. We found a significant 
association between hyperexpression of CAF-1/p60 and the occurrence of node and/or 
distant metastases in SM patients. These findings indicate that CAF-1 may have a role as 
novel, sensible proliferation and prognostic marker for CM. CAF-1 overexpression can be 
easily evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded tissue, 
and may constitute a potential useful adjunctive tool for pathologists for predicting the 
individual prognosis of melanoma patients. 
3.7.7 Remodeling proteins 
Recent studies have shown that SWI/SNF ATP dependent chromatin remodeling enzymes 
are involved in the molecular alterations occurring in melanoma (Saladi et al., 2010) and 
regulate the expression of genes important for tumor metastasis. SWI/SNF enzymes 
promote neural crest migration and differentiation and interact with Microphthalmia –
Associated Transcription Factor (MITF), a known lineage survival oncogene in melanoma 
(de la Serna et al., 2006; Matsumoto et al., 2006; Saladi et al., 2010). SWI/SNF are 
multisubunit complexes that contain either BRG1 or BRM as the catalytic subunit (Li B et al., 
2007) regulating important aspects of melanoma phenotype. While BRM expression is 
variable in melanoma (cell lines), BRG1 expression is increased at the protein levels in 
primary melanoma tumors compared to dysplastic nevi, and in most melanoma cell lines 
(Keenen et al., 2010; Vachtenheim et al., 2010). A BRG1 expression increases during 
melanoma progression and is thought to play an important role in melanoma metastasis, as 
it promotes melanoma invasive ability in vitro. This is supported by the ability of BRG1 to 
modulate the expression of a subset of cell surface receptors, adhesion proteins, and 
extracellular matrix remodeling enzymes in normal as in cancer cells, interacting with a 
transcriptional regulator of MMP2, the SP1 transcription factor, being also recruited to the 
matrix metalloproteinase (MMP2) promoter. However, up to date there was found no 
significant difference in BRG1 levels between primary and metastatic melanoma samples, 
but there has been evidenced a tendency for negative to weak BRG1 expression in the cases 
with a better patient survival (Lin et al., 2010). 
3.7.8 miRNA 
As before outlined, microRNAs (miRNAs) may act as either oncogenes or tumor suppressor 
genes. Recently, it has been shown that miRNAs act as tumor suppressors in uveal 
melanoma cells through downregulation of MITF and CDK6, and, particularly, that miR-137 
www.intechopen.com
Genetic, Epigenetic and Molecular Changes in  
Melanoma: A New Paradigm for Biological Classification 
 
49 
is frequently silenced in this tumor (Chen et al., 2011). Up to now, limited data are available 
on miRNA deregulation in CM, almost all relative to small series of cases (Mueller et al., 
2009; Sigalotti et al., 2010). However, a recent specific miRNA profiling study reports 
extensive modifications of miRNA patterns in CM as compared to normal melanocytes, and 
identifyies modifications of miRNA expression potentially associated to the different phases 
of CM progression (Mueller et al., 2009). Another study reports that miR-17-5p, miR-18a, 
miR-20a and miR-92a are over-expressed, while miR-146a, miR-146b, and miR155 are down-
regulated in the majority of the examined CM cell lines as compared to normal melanocytes 
(Levati et al., 2009). Of particular interest, the master regulator of melanocytes biology, 
transcription factor MITF, has been found to be regulated by at least 2 different miRNAs, miR-
137 and miR-182, which showed opposite alterations (Bemis et al., 2008). Other miRNAs have 
been found overexpressed in CM cell lines and tissues. Among them, miR-182 appeared to be 
involved in CM progression, being increasingly over-expressed from primary to metastatic 
disease. Its action has been related to the repression of MITF and FOXO3 (Segura. et al., 2009). 
The overexpression of miR-29c has been recently reported to be inversely correlated to 
DNMT3A and DNMT3B protein expression (Nguyen et al., 2011) and predictive of overall 
survival in AJCC stage III melanoma patients by multivariate analysis.  On the contrary,  
members of the let-7 family of miRNAs are significantly downregulated in primary 
melanomas compared with benign nevi (Schultz et al., 2008). As in normal cells let-7 miRNAs 
exhert a regulatory activity on the expression of cyclins D1, D3, and A, as well as cyclin-
dependent kinase (Cdk) 4, all of which have been described to play a role in melanoma 
development, (Müller & Bosserhoff, 2008). It appears evident that the loss of let-7a expression 
may contribute in the development and progression of melanoma.  
3.7.9 Epigenetic drugs 
DNA methylation inhibitors (as azacitidine and decitabine), along with inhibitors of histone 
deacetylation, have improved the therapeutic options of some cancer types, and particularly 
of several hematologic malignancies, where gene hypermethylation typically occurs (Baylin, 
2005). The potential reversibility of epigenetic changes via pharmacologic manipulation, 
confers to this area of research particular relevance for the alternative therapeutic treatment 
of patients with advanced melanoma. New agents affecting epigenetic alterations in 
melanoma are thus being increasingly produced. The treatment of CM with these 
“epigenetic drugs” generally produce multiple effects, due to the reactivation and/or 
suppression of many of intersecting pathways that became altered during melanoma 
progression (Sigalotti et al., 2007). There is a tendency to combine epigenetic intervention 
with conventional and/or innovative therapeutic approaches that would take specific 
advantages from the epigenetically-restored pathways. As an example,  strategies to restore 
the loss of expression of spindle checkpoint proteins, such as RASSF1A, by use of 
demethylating agents may be of utility in reversing genetic instability associated with 
melanoma progression (Rother & Jones, 2009). Indeed, in advanced stage melanoma, 
RASSF1A appears to correlate at some degree with response to chemotherapy. As a result, 
profiling of the activation state or degree of mitotic spindle dysfunction using these 
markers, shows promise in identifying those patients who would benefit from spindle 
toxins. The drugs typically used as multi-agent chemotherapy regimens to treat melanoma 
include carboplatin and cisplatin, alkylating agents, and mitotic spindle poisons such as 
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vinblastine and paclitaxel. Since therapeutic activity of alkylating agents and DNA-
damaging agents requires tumor cell division, melanomas with high proliferative rate or 
those with genetic alterations in checkpoint function may be more likely to respond (Rother 
& Jones, 2009). Similarly, a particular clinical benefit might be expected from the synergistic 
effect of the pharmacologic inhibition of DNA methyltransferases and/or of histone 
deacetylases with chemo-, radio-, and immuno-therapeutic approaches in melanoma 
patients (Sigalotti, 2010). The introduction of new epigenetic drugs in this context is  
 
 
a) RTK-RAS-RAF-MEK-ERK pathway. When activated, RAS triggers a phosphorylation cascade of RAF, 
MEK and ERK. MEK, when phosphorylated, activates Jun N-terminal kinase (JNK) cascade; ERK 
translocates to the nucleus, where it activates transcription factors for cell proliferation. VEGFR is a RTK 
and, therefore, when activated, leads to activation of this pathway. b) PI3K-AKT pathway. Activation of 
RTKs leads to activation of PI3K and, subsequently, of PDK1 that phosphorylates and activates AKT. 
AKT regulates several proteins affecting cell growth and survival. c) ROS signaling pathway. ROS 
production can induce HIF-1a (hypoxia-inducible transcription factors 1) under normoxia in response to 
some factors. Intracellular ROS activates also the NFkB (nuclear factor-kappa route B). d) DNA-repair 
pathways. PARP1 (Poly [ADP-ribose] polymerase 1) has a role in repair of single-stranded DNA 
(ssDNA) breaks, modifying nuclear proteins by polyADP-ribosylation. Component of the post-
replicative DNA mismatch repair system (hMSH2 and hMLH) binds to DNA mismatches thereby 
initiating DNA repair. e) The Chromatin Assembly Factor-1 (CAF-1) promotes also the first step of 
nucleosome assembly during DNA replication, driving the incorporation of different histones into DNA 
to the sites where chromatin has to be newly formed or remodeled. CAF-1 promotes chromosome 
assembly during resetting of the chromatin structure after DNA repair (d). 
Fig. 1. Crosstalks between signaling pathways involved in melanomagenesis and 
progression 
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GENETIC CHANGES  
Mutations 
ASIP, ǃ-catenin, BRAF, CCND1, CDKN2A, CDK4, Rb, 
cKIT, HIF1/ROS, IGFBP7, MC1R, NEUROPILIN2, NFkB, 
NRAS, PI3KCA, p16INK4, PLEXIN B1, PTEN/AKT, 
Rab38, TYR, TYRP1, WNT5A 
EPIGENETIC 
ALTERATIONS 
 
Hypermethylation 
ATM, APAF-1, APC, BRCA1, BRCA2, CASP8, CCR7, 
CXCR4, CDKN1B, CDKN1C, CDKN2A, CDKN2B, 
CYP1B1, DAPKb, ENC1, ER-ǂ, GDF15, GSTP, H3, HLA 
class I, HOXB13, HSPB6, HSPB8, HSP11, MAGE-A1, 
MGMT, MLH1, MSH2, NF12PTCHPTEN, NPM2, 
p101(PIK3R5), PGRbeta, PTEN, QPCT, RARǃ2, RASSF1A, 
RB1, RUNX3, SERPINB5, SOCS1, SOCS2, SOCS3, Stratifin 
(14-3-3sigma), SWI/SNF, TFAP2C, THBS4, TIMP3, TMS1, 
TNFRSF10C (DcR1), TNFRSF10D, TP53INP1, TP53/73, 
TPM1, TRAILR1, TSCL1, TSPY, XAF1, ZAR1 
Hypomethylation 
MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, Maspin, 
TSPY,  
Phosphorylation H3 (ser 28), H3 (ser 10) 
Acethylation 
E2F, H3, H4, MITF, p53, Rb, SWI/SNF (ATP)-dependent 
chromatin remodelling complex, 
Ubiquitination/SUMOylation 
H4, PCNA, Topoisomerase 1, Topoisomerase 2, MiTF, IkB, 
ǃ-catenin 
Chromatin assembly Chromatin Assembly Factor-1  (CAF-1) 
Remodelling proteins SWI/SNF chromatin remodelling enzymes 
miRNA overexpressed miR-29c, miR-17-5p, miR-18a, miR-20a, miR-92a, miR-182 
miRNA downregulated miR137, miR-146a, miR-146b, miR155, miRNA let-7a 
Tumor-stromal interactions MCSP/NG2 
Table 1. Summary of major genetic and epigenetic alterations in melanoma. 
expected to reduce systemic toxicities of traditional therapies. Histone deacetylase (HDAC) 
inhibitors represent a promising therapeutic option for melanoma treatment (Facchetti F et 
al., 2004) and are particularly interesting with this regard. It has been shown, in fact, that 
HDAC inhibitors enhance the response of human tumor cells to ionizing radiation (Munshi 
et al., 2006) and synergize with radiation, reducing the clonogenic survival of CM cells. This 
beneficial effect seems to be related to their ability to sensitize CM cells to radiation-induced 
apoptosis, impairing also the ability of CM cells to repair DNA damages through the down-
regulation of the repair proteins Ku70, Ku80, Ku86 and Rad50) (Munshi et al., 2006). These 
exciting results support the idea that combined epigenetic chemo/radiotherapies might 
overcome the resistance of CM to traditional therapies. In addition, HDAC inhibitors have 
been shown to sensitize melanoma cells to retinoid treatment, leading to the increase of tsg 
p16INK4A, either mutated or with homozygous deletion in most of late-stage melanoma 
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cells, thus correlating with their increased senescence. A further interesting example of 
possible integration between “old” and “new, epigenetic” therapies, is offered by the major 
polyphenolic constituent of green tea, the epigallocatechin-3-gallate (EGCG), which has anti-
proliferative, pro-apoptotic and chemopreventive effects against cancer cells, including 
melanoma (Nihal et al., 2010), mediated through its demethylating activity. EGCG sensitizes 
melanoma cells to interferon in mouse models of human melanoma, by down-regulating NF-
κB promoter activity, induced by reactive oxygen species (Fried & Arbiser, 2008). EGCG 
synergizes with the HDAC inhibitory action of vorinostat to help de-repress silenced tumor-
suppressor genes regulating key functions, such as proliferation and survival. Lastly, it has to 
be outlined the potential beneficial effect of therapeutically restoring miRNA activity in CM.  
4. Conclusions 
Cross-talk between different signaling cascades has emerged as a paradigm of cell biology, 
in that they direct the local and global cell functions (Fischle et al., 2003). The epigenetic 
code is made of post-translational marks which correlate with specific transcriptional states 
and may influence one another (Berger, 2002), their combinations ultimately directing 
downstream functions. We are beginning to unravel the complexities of gene expression, 
which is conditioned by a myriad of diverse stimuli, acting in a multidimensional fashion 
(Dong & Bode, 2006), with histone modification and ATP-dependent chromatin remodeling 
being functionally connected for gene regulation. DNA methylation is controlled at several 
different levels in normal and tumor cells, directly by DNA methyltransferases (DNMTs), 
and indirectly by nucleosome spacing and histone deacetylases (HDACs) (Baylin, 2005; Bird 
A, 2002; Bird & Wolffe, 1999). Synergism/antagonism of adjacent modifications in the same 
histone tail is the rule (‘cis’ effects), but modifications on different histones affect each other 
(‘trans’ effects) (Fischle et al., 2003). Overall, it is now clear that each specific genetic or 
epigenetic alteration may impact the biology of CM cells by concurrently affecting multiple 
proteins/pathways. Further study will determine which panels of genes are most effective 
as biomarkers for prediction of response to therapy and prognosis and may be translated 
into clinically applicable tests. The different methylation or acetylation patterns may 
indicate important differences in tumorigenesis and may help identify subsets of patients 
with different clinical behaviour. The reported correlation of alterations in tumour DNA 
with circulating tumour DNA allows the basis for the development of biomarker blood tests 
for early detection of melanoma metastasis and prediction of response to therapy. Being a 
relatively rare event in normal melanocytes, specific hypermethylations of CpG islands are 
ideal candidate as biomarkers for early melanoma metastasis detection in body fluids 
(Howell et al., 2009). In line with this hypothesis, it has been recently reported that estrogen 
receptor A (ER-A) methylation can predicts melanoma progression, and serum methylated 
ER-A constitutes an unfavorable prognostic factor and negative predictor of progression-
free survival in patients treated with biochemotherapy (Mori et al., 2006; Satzger I, 2009). 
Many studies are investigating the methylation status of several genes in sera of CM 
patients (Satzger I, 2009). We have now summarized only a selection of the hot topics 
concerning the genetic and epigenetic alterations that contribute to the development and 
progression of melanoma. Many questions remain unanswered. Cancer research is moving 
away from an histology-based view of cancer toward a genomic concept of the neoplastic 
disease (Garraway, 2010), and therapy is shifting toward pharmacogenomics, engineered to 
hit the specific genetic and epigenetic profile (the "genomic grade") of the single tumor in 
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each single patient, (Kim et al., 2010; Piccart-Gebhart, 2010). These goals are necessary for 
ultimately improve melanoma patient outcomes and increase drug efficacy against this 
lethal cancer. Further work is required to improve our understanding of the precise role of 
interlinked modifications that dictate specific genomic states, such as gene activation, 
repression, DNA repair in melanoma progression. Bioinformatics-based tools are being 
currently used to generate complex fingerprints based on a combination of genetic and 
epigenetic markers. Recent mathematical modeling of the dynamics of transcriptional 
control of gene expression will be relevant to a full understanding of MITF, SOX10, and 
PAX3 functions (Ben-Tabou de-Leon & Davidson, 2009). An unconditioned approach to the 
importance of the yet known key molecules involved in melanocyte development and 
function, under the light of the growing body of newly discovered interrelationships 
between new and old members of the most relevant pathways involved in melanoma 
progression, will be fundamental to improve the chances of the pigment research 
community to fight melanoma. The shift occurring towards personalized therapy in cancer 
is also beginning to be seen in melanoma, and new generation epigenetic drugs are be 
expected to reduce systemic toxicities with more specific effects (Sigalotti et al., 2010), even if 
additional pre-clinical studies are required to define even more precisely their consequences 
on normal cells and to predict their safety when used on patients. Convincing evidence that 
we are on the right way to truly understand melanoma biology already exists. A 
comprehensive point-of-view, considering simultaneously the phenotype, genotype and 
epigenotype of melanoma cells with respect to the differences in clinical behavior 
(Shackleton & Quintana, 2010) will help us to guide treatment and target those patients with 
specific, personalized therapies. 
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